कृपया अन्य खोज का प्रयास करें
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Ting Yuk Wu | 67 | 2020 | Independent Non-Executive Director |
Ye Liu | 50 | 2018 | CEO & Executive Director |
Yumeng Wang | 31 | 2021 | Non-Executive Director |
Yiran Huang | 67 | 2020 | Independent Non-Executive Director |
Yanling Cao | 38 | 2019 | Non-Executive Director |
Zhenyu Zhang | 46 | 2022 | Independent Non-Executive Director |
Zhaopeng Hu | 50 | 2020 | Chief Development Officer & Executive Director |
Lian Yong Chen | 60 | 2018 | Non-Executive Chairman of the Board |
Wei Li | 51 | 2018 | Non-Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है